ERBB2 and breast carcinoma: The European Society for Medical Oncology (ESMO) and the National Comprehensive Cancer Network (NCCN) guidelines have recommended trastuzumab as standard neoadjuvant therapy for HER2+ve breast cancer and trastuzumab combined with pertuzumab for high-risk patients with node positivity and/or estrogen receptor negativity [6,7].